- In March 2023, Moderna, announced the expansion of its mRNA vaccine program, specifically engineered for addressing emerging infectious diseases and cancer therapies in resource-limited settings. This innovative approach is designed to enhance global health security, offering a reliable and effective solution for pandemic preparedness and oncology. This advancement highlights Moderna's commitment to developing cutting-edge medical technologies that safeguard vulnerable populations, ensuring greater protection and improved public health outcomes for institutions and their communities
- In September 2023, Moderna announced positive clinical results across its cancer, rare disease, and infectious disease franchises at its annual R&D Day. The company emphasized its mRNA platform's success in advancing respiratory disease programs to positive Phase 3 data and its goal to launch up to 15 products in five years, including in oncology and infectious diseases, indicating significant pipeline expansion
- In October 2023, Gilead Sciences presented late-breaking data across its liver disease pipeline, including final results from a pivotal Phase 3 study for bulevirtide in hepatitis delta, and initial results from a Phase 1a study of a novel investigational therapeutic vaccine for hepatitis B. The company also showcased real-world data on hepatitis C treatments, reinforcing its leadership in viral hepatitis and liver disease
